Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georg Lenz

Showing results (231-240 of 294) with videos related to

Pageof 30
Sort By:
The Journal of Experimental Medicine|March 14, 2007
Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphomaGeorg Lenz, Inga Nagel, Reiner Siebert, et al.
Leukemia|June 21, 2020
A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapyMaxi Wass, Stefanie Göllner, Birgit Besenbeck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2017
Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study GroupAnnette M Staiger, Marita Ziepert, Heike Horn, et al.
Hemasphere|February 26, 2026
Autologous stem cell transplantation in major T-cell lymphoma entities: An analysis by the EBMT Lymphoma Working PartyEvgenii Shumilov, Maud Ngoya, Philipp Berning, et al.
Hemasphere|September 25, 2025
Large B-cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-upCatherine Thieblemont, Maria Gomes Da Silva, Sirpa Leppä, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|March 13, 2019
Favorable radiation field decrease in gastric marginal zone lymphoma : Experience of the German Study Group on Gastrointestinal Lymphoma (DSGL)Gabriele Reinartz, Regina P Pyra, Georg Lenz, et al.
Nature Medicine|November 25, 2014
Disruption of the PRKCD-FBXO25-HAX-1 axis attenuates the apoptotic response and drives lymphomagenesisUrsula Baumann, Vanesa Fernández-Sáiz, Martina Rudelius, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2019
Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B CellsElizabeth A Lemm, Beatriz Valle-Argos, Lindsay D Smith, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 8, 2014
Mapping of transcription factor motifs in active chromatin identifies IRF5 as key regulator in classical Hodgkin lymphomaStephan Kreher, M Amine Bouhlel, Pierre Cauchy, et al.
Haematologica|May 7, 2011
High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapyTeresa M Cardesa-Salzmann, Luis Colomo, Gonzalo Gutierrez, et al.
Pageof 30

Showing results (231-240 of 294) with videos related to

Sort By:
Pageof 30
The Journal of Experimental Medicine|March 14, 2007
Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphomaGeorg Lenz, Inga Nagel, Reiner Siebert, et al.
Leukemia|June 21, 2020
A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapyMaxi Wass, Stefanie Göllner, Birgit Besenbeck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2017
Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study GroupAnnette M Staiger, Marita Ziepert, Heike Horn, et al.
Hemasphere|February 26, 2026
Autologous stem cell transplantation in major T-cell lymphoma entities: An analysis by the EBMT Lymphoma Working PartyEvgenii Shumilov, Maud Ngoya, Philipp Berning, et al.
Hemasphere|September 25, 2025
Large B-cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-upCatherine Thieblemont, Maria Gomes Da Silva, Sirpa Leppä, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|March 13, 2019
Favorable radiation field decrease in gastric marginal zone lymphoma : Experience of the German Study Group on Gastrointestinal Lymphoma (DSGL)Gabriele Reinartz, Regina P Pyra, Georg Lenz, et al.
Nature Medicine|November 25, 2014
Disruption of the PRKCD-FBXO25-HAX-1 axis attenuates the apoptotic response and drives lymphomagenesisUrsula Baumann, Vanesa Fernández-Sáiz, Martina Rudelius, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2019
Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B CellsElizabeth A Lemm, Beatriz Valle-Argos, Lindsay D Smith, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 8, 2014
Mapping of transcription factor motifs in active chromatin identifies IRF5 as key regulator in classical Hodgkin lymphomaStephan Kreher, M Amine Bouhlel, Pierre Cauchy, et al.
Haematologica|May 7, 2011
High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapyTeresa M Cardesa-Salzmann, Luis Colomo, Gonzalo Gutierrez, et al.
Pageof 30